LRIG1 is a Triple Threat: ERBB Negative Regulator, Intestinal Stem Cell Marker and Tumour Suppressor

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Apr 6

PMID 23558895

Citations 50

Authors

Y Wang

E J Poulin

R J Coffey

Affiliations

Soon will be listed here.

Abstract

In baseball parlance, a triple threat is a person who can run, hit and throw with aplomb. Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a cell surface protein that antagonises ERBB receptor signalling by downregulating receptor levels. Over 10 years ago, Hedman et al postulated that LRIG1 might be a tumour suppressor. Recently, Powell et al provided in vivo evidence substantiating that claim by demonstrating that Lrig1 loss in mice leads to spontaneously arising, highly penetrant intestinal adenomas. Interestingly, Lrig1 also marks stem cells in the gut, suggesting a potential role for Lrig1 in maintaining intestinal epithelial homeostasis. In this review, we will discuss the ability of LRIG1 to act as a triple threat: pan-ERBB negative regulator, intestinal stem cell marker and tumour suppressor. We will summarise studies of LRIG1 expression in human cancers and discuss possible related roles for LRIG2 and LRIG3.

Citing Articles

Extended range proteomic analysis of blood plasma from schizophrenia patients.

Petrovskiy D, Butkova T, Nikolsky K, Kopylov A, Nakhod V, Kulikova L Front Mol Biosci. 2024; 11:1483933.

PMID: 39640846 PMC: 11617367. DOI: 10.3389/fmolb.2024.1483933.

Immunoreactivity of LMO7 and other molecular markers as potential prognostic factors in oropharyngeal squamous cell carcinoma.

Israelsson P, Oda H, Ofverman C, Stefansson K, Lindquist D BMC Oral Health. 2024; 24(1):729.

PMID: 38918827 PMC: 11197244. DOI: 10.1186/s12903-024-04510-4.

LRIG1 engages ligand VISTA and impairs tumor-specific CD8 T cell responses.

Ta H, Roy D, Zhang K, Alban T, Juric I, Dong J Sci Immunol. 2024; 9(95):eadi7418.

PMID: 38758807 PMC: 11334715. DOI: 10.1126/sciimmunol.adi7418.

Intestinal permeability correlates with disease activity and DNA methylation changes in lupus patients.

Bowes M, Casares-Marfil D, Sawalha A Clin Immunol. 2024; 262:110173.

PMID: 38460891 PMC: 11009052. DOI: 10.1016/j.clim.2024.110173.

CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.

Hibler W, Merlino G, Yu Y Cells. 2023; 12(23).

PMID: 38067178 PMC: 10706172. DOI: 10.3390/cells12232750.

References

Hedman H, Lindstrom A, Tot T, Stendahl U, Henriksson R, Hellberg D . LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol. 2010; 49(6):812-5. DOI: 10.3109/0284186X.2010.492789. View

Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S . Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res. 2010; 317(4):504-12. DOI: 10.1016/j.yexcr.2010.11.005. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S . Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett. 2002; 521(1-3):67-71. DOI: 10.1016/s0014-5793(02)02824-7. View

Stutz M, Shattuck D, Laederich M, Carraway 3rd K, Sweeney C . LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene. 2008; 27(43):5741-52. PMC: 3175812. DOI: 10.1038/onc.2008.185. View

Fero M, Randel E, Gurley K, Roberts J, Kemp C . The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998; 396(6707):177-80. PMC: 5395202. DOI: 10.1038/24179. View

Ljuslinder I, Golovleva I, Palmqvist R, Oberg A, Stenling R, Jonsson Y . LRIG1 expression in colorectal cancer. Acta Oncol. 2007; 46(8):1118-22. DOI: 10.1080/02841860701426823. View

Ghasimi S, Haapasalo H, Eray M, Korhonen K, Brannstrom T, Hedman H . Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression. J Neurooncol. 2012; 108(3):435-41. DOI: 10.1007/s11060-012-0856-x. View

Sheu J, Lee C, Ko J, Tsao G, Wu C, Fang C . Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2709-16. DOI: 10.1158/1055-9965.EPI-09-0349. View

10.

Lee J, Kim B, Lee S, Jeong Y, Oh Y, Song Y . Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene. 2012; 33(1):34-43. DOI: 10.1038/onc.2012.551. View

11.

Ostroff R, Bigbee W, Franklin W, Gold L, Mehan M, Miller Y . Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One. 2010; 5(12):e15003. PMC: 2999620. DOI: 10.1371/journal.pone.0015003. View

12.

Wong V, Stange D, Page M, Buczacki S, Wabik A, Itami S . Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol. 2012; 14(4):401-8. PMC: 3378643. DOI: 10.1038/ncb2464. View

13.

Hedman H, Nilsson J, Guo D, Henriksson R . Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?. Acta Oncol. 2002; 41(4):352-4. DOI: 10.1080/028418602760169398. View

14.

Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J . LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004; 23(16):3270-81. PMC: 514515. DOI: 10.1038/sj.emboj.7600342. View

15.

Maitra A, Wistuba I, Washington C, Virmani A, Ashfaq R, Milchgrub S . High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol. 2001; 159(1):119-30. PMC: 1850416. DOI: 10.1016/S0002-9440(10)61679-3. View

16.

Goldoni S, Iozzo R, Kay P, Campbell S, McQuillan A, Agnew C . A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene. 2006; 26(3):368-81. DOI: 10.1038/sj.onc.1209803. View

17.

Lindstrom A, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H . LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer. 2007; 18(2):312-7. DOI: 10.1111/j.1525-1438.2007.01021.x. View

18.

Thomasson M, Hedman H, Ljungberg B, Henriksson R . Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. BMC Res Notes. 2012; 5:216. PMC: 3419632. DOI: 10.1186/1756-0500-5-216. View

19.

Zhang H, Yan Q, Xu S, Ou Y, Ye F, Wang B . Association of expression of Leucine-rich repeats and immunoglobulin-like domains 2 gene with invasiveness of pituitary adenoma. J Huazhong Univ Sci Technolog Med Sci. 2011; 31(4):520. DOI: 10.1007/s11596-011-0483-3. View

20.

Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson J, Josefsson A . LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer. 2010; 128(12):2843-52. DOI: 10.1002/ijc.25820. View